Thrombin generation markers and coronary heart disease risk factors in a Polish population sample

Thrombosis and Haemostasis

Volumn 77, Issue 4, 1997, Pages 697-700

  Musiał, Jacek ^a   Paja̧k, Andrzej ^a   Undas, Anetta ^a   Kawalec, Ewa ^a   Topór Ma̧dry, Roman ^a   Pazucha, Tadeusz ^a   Grzywacz, Marek ^a   Szczeklik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTHROMBIN; THROMBIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLAND; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030942935     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656036     Document Type: Article

References (29)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes: Part 1. N Engl J Med 1992; 326: 242-50.
2. Nachman RL. Thrombosis and atherogenesis: Molecular connections. Blood 1992; 79: 1897-906.
3. Bauer K. Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-9.
4. Prisco D. Markers of increased thrombin generation. Res Clin Lab 1990; 20: 217-25.
5. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta analysis and review of a literature. Ann Intern Med 1993; 118: 956-63.
6. Eber B, Schumacher M. Fibrinogen: its role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993; 19: 104-7.
7. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res 1993; 70: 1-38.
8. Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990; 85: 169-73.
9. Rywik S, Sznajd J, Przestalska H, Magdon M, Wagrowska H, Pajak A, Kulesza W, Celinski A, Kupsc W, Konarska R. Monitoring of cardiovascular incidence, fatality and mortality trends and their determinants - longitudinal study Pol-MONICA. Part I: Methodological principals of the study. Przeg Lek 1985; 42: 250-5.
10. Rywik S, Paja̧k A, Kupsc W, Baczynska E, Sznajderman M, Celinski A, Kulesza W, Czernecka H, Przestalska H, Idzior B, Wagrowska H, Malczewska M, Mizera R. Monitoring of cardiovascular incidence, fatality and mortality trends and their determinants - longitudinal study Pol-MONICA. Part III: Principals of standardization and quality control. Przeg Lek 1985; 42: 280-6.
11. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1987; 19: 65-70.
12. Friedewald WT, Levy RI, Friedrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-504.
13. Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Ostermann H, van de Loo J. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993; 70: 550-3.
14. 1+2: correlations with cardiovascular risk factors. Blood Coagulation and Fibrinolysis 1994; 5: 335-40.
15. Giansante C, Fiotti N, Cattin L, Da Col PG, Calabrese S. Fibrinogen, D-Dimer and thrombin-antithrombin complexes in a random population sample: Relationships with other cardiovascular risk factors. Thromb Haemost 1994; 71: 581-6.
16. Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD. The effects of quality and timing of venipuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost 1995; 73: 82-6.
17. Hafner G, Schinzel H, Ehrental W, Wagner C, Konheiser U, Zotz R, Lotz J, Blank R, Weilemann LS, Prellwitz W. Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1+2 and thrombin-antithrombin III complex. Ann Hematol 1993; 67: 121-5.
18. Cadroy Y, Pierrejean D, Fontan B, Sié P, Boneu B. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol 1992; 34: 43-6.
19. Estivals M, Pelzer H, Sié P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1+2, thrombin-antithrombin III complex and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol 1991; 78: 421-4.
20. 1+2. Thromb Haemost 1993; 70: 253-8.
21. Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic changes that constitute the hypercoagulable state. Lancet 1991; II: 1079.
22. Folsom AR. Epidemiology of fibrinogen. Eur Heart J 1995; 16 (suppl A): 21-23.
23. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7.
24. Davi G, Ganci A, Averna M, Giammarresi C, Brabagallo C, Catalano I, Cala A, Notarbartolo A. Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thromb Haemost 1995; 74: 1015-9.
25. Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minimikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993; 44: 112-6.
26. Kario K, Matsuo T. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. Atherosclerosis 1993; 103: 131-6.
27. Szczeklik A. Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. Thromb Haemost 1995; 74: 77-80.
28. Szczeklik A, Musial J, Undas A, Swadźba J, Góra PF, Piwowarska W, Duplaga M. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 948-54.
29. Donders SH, Lustermans FA, van Wersch JW. Prothrombin fragment 1.2 in both treated and untreated hypertensive patients. Neth J Med 1993; 43: 174-8.